Chronic Fatigue Therapy™ Homeopathic Fast Dissolving Tablets

Manufacturer: TRP Company
Effective date: 2012-10-30
Label type: HUMAN OTC DRUG LABEL
Version: 1
Source: full-release
Hydrated at: 2026-06-01 02:04:05

Label at a glance#

ProductChronic Fatigue Therapy

Active ingredientEPINEPHRINE, GOLD, HUMAN BREAST TUMOR CELL, ECHINACEA, UNSPECIFIED, GELSEMIUM SEMPERVIRENS ROOT, GINKGO, INFLUENZA B VIRUS, PHOSPHORIC ACID, SCUTELLARIA LATERIFLORA TOP

Label structure9 sections

Indications and uses

According to homeopathic indications, these ingredients provide temporary relief of Chronic Fatigue for symptoms such as: • Fatigue • Memory Loss • Insomnia • Weakness • Exhaustion • Muscle • Pain • Sore Throat after diagnosis by a physician.

Dosage and administration

Suitable for adults and children 12 years and above. Dissolve entire tablet under tongue. Do not chew or swallow whole. Take 1 tablet 3 times a day or as directed by a physician. Use up to 6 times a day as needed. Take at least 10 minutes before or at least 10 minutes after eating or drinking. Children under the age of 12: consult a physician before use.

Contacts and useful links#

PhoneLabel contact888-969-6855

Label contents#

Full prescribing information#

OTC - ACTIVE INGREDIENT SECTION

Active Ingredients		Purpose
Adrenalinum HPUS	3x, 6x, 12x	Physical fatigue, muscle pain
Aurum met. HPUS	8x, 12x 18x	Memory loss, melancholy
Carcinosin HPUS	24x	Post chronic illness fatigue, excessive weariness
Echinacea HPUS	3x, 6x, 12x	Immune support, general fatigue
Gelsemium HPUS	6x, 12x, 18x	Burnout, sore throat, headache
Ginkgo biloba HPUS	3x, 6x, 12x	Vitality support, poor concentration, forgetfulness
Influenzinum HPUS	12x, 24x	Post viral fatigue, weakness
Phosphoricum Acidum HPUS	6x, 12x, 18x	Nervous system fatigue, insomnia
Scutellaria HPUS	6x, 12x, 18x	Apathy, weakness, restlessness

The letters HPUS indicate that the components of this product are officially monographed in the Homeopathic Pharmacopoeia of the United States.

Uses

INDICATIONS & USAGE SECTION

Warnings

WARNINGS SECTION

USE ONLY AFTER DIAGNOSIS BY A PHYSICIAN.

This product is intended to complement, not replace, standard medical treatment.
Initial worsening of symptoms may occur.
A physician should always be consulted to rule out serious causes.
In case of overdose, get medical help or contact a Poison Control Center right away.

Stop use and ask a doctor if:

You experience worsening symptoms.
If symptoms last longer than 7 days.

OTC - PREGNANCY OR BREAST FEEDING SECTION

If pregnant or breast-feeding, ask a health professional before use.

Directions

DOSAGE & ADMINISTRATION SECTION

Suitable for adults and children 12 years and above.
Dissolve entire tablet under tongue.
Do not chew or swallow whole.
Take 1 tablet 3 times a day or as directed by a physician.
Use up to 6 times a day as needed.
Take at least 10 minutes before or at least 10 minutes after eating or drinking.
Children under the age of 12: consult a physician before use.

Other information

SPL UNCLASSIFIED SECTION

Active ingredients are micro-diluted in accordance with the Homeopathic Pharmacopoeia of the United States and are therefore non-toxic with no known side effects.
Store in a cool dark location.

Inactive Ingredients

INACTIVE INGREDIENT SECTION

Advantol® 300, Lactose, Magnesium Stearate, Mannitol, Microcrystalline Cellulose.

OTC - QUESTIONS SECTION

For more information and to order related products call toll free: 888-969-6855 or trpcompany.com

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

DailyMed Product Concepts#

Product concept, Relation, Version table
Product concept	Relation	Version	Effective
0b4ec9ca-d305-43fc-88dd-7a510313efe0	Product name	1	20260105
bb209f42-a85f-4fee-9d3d-c9dded168625	Product name	1	20251208
49628fc7-2031-4c28-bd31-0ef3aa8f44a3	Product name	3	20251118
cbf85893-59ef-423f-87d4-a573c000a8b9	Product name	8	20250731
b5b1095b-40cd-8a9e-b111-502545045b07	Product name	4	20250325
e190029e-423b-473c-8e04-2ada59b5b711	Product name	1	20250314
e0031c74-3853-42bc-8e10-86dbbe83992e	Product name	2	20231116
f7046b89-2016-499a-adc6-78479172abc6	Product name	1	20230425
a62a50ac-1535-4461-9768-8ae703e2e9fb	Product name	1	20210525
2686d634-e712-4007-8dbf-3d37c6c4d71f	Product name	1	20181121
fa8b5901-e681-426f-82fe-54f6d81ec698	Product name	4	20180619
bd49bb86-2d32-4a7a-a594-eeda2e29af42	Product name	1	20180118
c08ab52f-2fc8-4409-9d9f-ed8edc0bd070	Product name	1	20171221
3becbe78-12d9-4ad2-9b4c-1e36f8d1303a	Product name	1	20170815
6084a4f4-5437-c9a5-caec-5361ee075a59	Product name	1	20140508
90c5639a-61b0-88d6-ddcf-21888e94869a	Product name	1	20140508
9514609b-a2a9-f8ec-6ba6-3f8e5ee89877	Product name	1	20140508
bc07ef78-e82d-0c19-31f4-31f263780582	Product name	1	20140508

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDC	Effective	Action	Document	Indexing SPL	Related label
17312-020-14	2020-01-31	C162847	48780-1	9d75b9d0-3aed-f424-e053-dadaa90a57ce	Chronic Fatigue Therapy™ Homeopathic Fast Dissolving Tablets

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDC	Product	Description	Form	Quantity	Strength	SPL version
17312-020-14	Chronic Fatigue Therapy	1 in 1 PACKAGE	TABLET, ORALLY DISINTEGRATING	1		1
17312-020-14	Chronic Fatigue Therapy	70 in 1 BOTTLE	TABLET, ORALLY DISINTEGRATING	70		1

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDC	Dashboard title	SPL version	Validation	Dashboard ZIP
17312-020	CHRONIC FATIGUE THERAPY (EPINEPHRINE - GOLD - HUMAN BREAST TUMOR CELL - ECHINACEA, UNSPECIFIED - GELSEMIUM SEMPERVIRENS ROOT - GINKGO - INFLUENZA B VIRUS - PHOSPHORIC ACID - SCUTELLARIA LATERIFLORA TOP -) TABLET, ORALLY DISINTEGRATING [TRP COMPANY]	1	Legacy NDC, 2 package rows	20121031_1999abf5-0817-44cd-aceb-b20e910e3064.zip

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
Ingredient	Type	UNII	SPL version
ECHINACEA, UNSPECIFIED	ACTIVE INGREDIENT	4N9P6CC1DX	1
EPINEPHRINE	ACTIVE INGREDIENT	YKH834O4BH	1
GELSEMIUM SEMPERVIRENS ROOT	ACTIVE INGREDIENT	639KR60Q1Q	1
GINKGO	ACTIVE INGREDIENT	19FUJ2C58T	1
GOLD	ACTIVE INGREDIENT	79Y1949PYO	1
HUMAN BREAST TUMOR CELL	ACTIVE INGREDIENT	C62OO7VD9K	1
INFLUENZA B VIRUS	ACTIVE INGREDIENT	1314JZ2X6W	1
PHOSPHORIC ACID	ACTIVE INGREDIENT	E4GA8884NN	1
SCUTELLARIA LATERIFLORA TOP	ACTIVE INGREDIENT	C6CNB75R61	1
ECHINACEA, UNSPECIFIED	ACTIVE MOIETY	4N9P6CC1DX	1
EPINEPHRINE	ACTIVE MOIETY	YKH834O4BH	1
GELSEMIUM SEMPERVIRENS ROOT	ACTIVE MOIETY	639KR60Q1Q	1
GINKGO	ACTIVE MOIETY	19FUJ2C58T	1
GOLD	ACTIVE MOIETY	79Y1949PYO	1
HUMAN BREAST TUMOR CELL	ACTIVE MOIETY	C62OO7VD9K	1
INFLUENZA B VIRUS	ACTIVE MOIETY	1314JZ2X6W	1
PHOSPHORIC ACID	ACTIVE MOIETY	E4GA8884NN	1
SCUTELLARIA LATERIFLORA TOP	ACTIVE MOIETY	C6CNB75R61	1
CELLULOSE, MICROCRYSTALLINE	INACTIVE INGREDIENT	OP1R32D61U	1
COPOVIDONE	INACTIVE INGREDIENT	D9C330MD8B	1
CROSPOVIDONE	INACTIVE INGREDIENT	68401960MK	1
LACTOSE	INACTIVE INGREDIENT	J2B2A4N98G	1
MAGNESIUM STEARATE	INACTIVE INGREDIENT	70097M6I30	1
MANNITOL	INACTIVE INGREDIENT	3OWL53L36A	1
SILICON DIOXIDE	INACTIVE INGREDIENT	ETJ7Z6XBU4	1
SORBITOL	INACTIVE INGREDIENT	506T60A25R	1

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 19 matching rows.

Chronic Fatigue Therapy
EPINEPHRINE - GOLD - HUMAN BREAST TUMOR CELL - ECHINACEA, UNSPECIFIED - GELSEMIUM SEMPERVIRENS ROOT - GINKGO - INFLUENZA B VIRUS - PHOSPHORIC ACID - SCUTELLARIA LATERIFLORA TOP -
EPINEPHRINE
GOLD
HUMAN BREAST TUMOR CELL
ECHINACEA, UNSPECIFIED
GELSEMIUM SEMPERVIRENS ROOT
GINKGO
INFLUENZA B VIRUS
PHOSPHORIC ACID
SCUTELLARIA LATERIFLORA TOP
MANNITOL
SORBITOL
CROSPOVIDONE
CELLULOSE, MICROCRYSTALLINE
COPOVIDONE
SILICON DIOXIDE
LACTOSE
MAGNESIUM STEARATE

NDC Codes#

Product NDC, Package NDC table
Product NDC	Package NDC
17312-020	17312-020-14

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 17 matching rows.

Name, UNII, Kind table
Name	UNII	Kind
EPINEPHRINE	YKH834O4BH	ACTIB
GOLD	79Y1949PYO	ACTIB
HUMAN BREAST TUMOR CELL	C62OO7VD9K	ACTIB
ECHINACEA, UNSPECIFIED	4N9P6CC1DX	ACTIB
GELSEMIUM SEMPERVIRENS ROOT	639KR60Q1Q	ACTIB
GINKGO	19FUJ2C58T	ACTIB
INFLUENZA B VIRUS	1314JZ2X6W	ACTIB
PHOSPHORIC ACID	E4GA8884NN	ACTIB
SCUTELLARIA LATERIFLORA TOP	C6CNB75R61	ACTIB
MANNITOL	3OWL53L36A	IACT
SORBITOL	506T60A25R	IACT
CROSPOVIDONE	68401960MK	IACT
CELLULOSE, MICROCRYSTALLINE	OP1R32D61U	IACT
COPOVIDONE	D9C330MD8B	IACT
SILICON DIOXIDE	ETJ7Z6XBU4	IACT
LACTOSE	J2B2A4N98G	IACT
MAGNESIUM STEARATE	70097M6I30	IACT

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 5 · 277 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredient	IID ingredient	UNII	Dosage form / route	Potency	Maximum daily exposure	Match
MANNITOL	MANNITOL	3OWL53L36A	LOZENGE / ORAL		20546 mg	Exact identifier — unii candidate 65 equally ranked IID candidates
LACTOSE	LACTOSE	J2B2A4N98G	INJECTION, SOLUTION / INTRAVENOUS	0.45 %w/v		Exact identifier — unii candidate 36 equally ranked IID candidates
SORBITOL	SORBITOL	506T60A25R	SOLUTION / NASAL	25 mg/1ml		Exact identifier — unii candidate 44 equally ranked IID candidates
MANNITOL	MANNITOL	3OWL53L36A	INJECTION / INTRAVENOUS		15200 mg	Exact identifier — unii candidate 65 equally ranked IID candidates
LACTOSE	LACTOSE	J2B2A4N98G	TABLET, FILM COATED, EXTENDED RELEASE / ORAL		620 mg	Exact identifier — unii candidate 36 equally ranked IID candidates
LACTOSE	LACTOSE	J2B2A4N98G	GRANULE, FOR SUSPENSION / ORAL	512.5 mg/5ml		Exact identifier — unii candidate 36 equally ranked IID candidates
SORBITOL	SORBITOL	506T60A25R	LOTION / TOPICAL	10.7 %w/w		Exact identifier — unii candidate 44 equally ranked IID candidates
MANNITOL	MANNITOL	3OWL53L36A	SPRAY / NASAL	41.5 mg		Exact identifier — unii candidate 65 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINE	MICROCRYSTALLINE CELLULOSE	OP1R32D61U	TABLET, COATED / ORAL		920 mg	Exact identifier — unii candidate 28 equally ranked IID candidates
MAGNESIUM STEARATE	MAGNESIUM STEARATE	70097M6I30	RING / VAGINAL		2 mg	Exact identifier — unii candidate 39 equally ranked IID candidates
SILICON DIOXIDE	SILICON DIOXIDE	ETJ7Z6XBU4	TABLET, FILM COATED, EXTENDED RELEASE / ORAL		336 mg	Exact identifier — unii candidate 49 equally ranked IID candidates
MAGNESIUM STEARATE	MAGNESIUM STEARATE	70097M6I30	DROPS / ORAL	NA		Exact identifier — unii candidate 39 equally ranked IID candidates
MAGNESIUM STEARATE	MAGNESIUM STEARATE	70097M6I30	TABLET, CHEWABLE, EXTENDED RELEASE / ORAL		9 mg	Exact identifier — unii candidate 39 equally ranked IID candidates
SILICON DIOXIDE	SILICON DIOXIDE	ETJ7Z6XBU4	TAMPON / VAGINAL	NA		Exact identifier — unii candidate 49 equally ranked IID candidates
MAGNESIUM STEARATE	MAGNESIUM STEARATE	70097M6I30	IMPLANT / SUBCUTANEOUS	0.5 mg		Exact identifier — unii candidate 39 equally ranked IID candidates
MANNITOL	MANNITOL	3OWL53L36A	CAPSULE, COATED PELLETS / ORAL		14 mg	Exact identifier — unii candidate 65 equally ranked IID candidates
MANNITOL	MANNITOL	3OWL53L36A	TABLET, FILM COATED, EXTENDED RELEASE / ORAL		543 mg	Exact identifier — unii candidate 65 equally ranked IID candidates
MAGNESIUM STEARATE	MAGNESIUM STEARATE	70097M6I30	TABLET / ORAL		980 mg	Exact identifier — unii candidate 39 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINE	MICROCRYSTALLINE CELLULOSE	OP1R32D61U	TABLET, DELAYED RELEASE / ORAL		2210 mg	Exact identifier — unii candidate 28 equally ranked IID candidates
MANNITOL	MANNITOL	3OWL53L36A	INJECTION, POWDER, FOR SUSPENSION / SUBCUTANEOUS		180 mg	Exact identifier — unii candidate 65 equally ranked IID candidates
SILICON DIOXIDE	SILICON DIOXIDE	ETJ7Z6XBU4	CAPSULE, COATED, EXTENDED RELEASE / ORAL	NA		Exact identifier — unii candidate 49 equally ranked IID candidates
SORBITOL	SORBITOL	506T60A25R	SUSPENSION / RECTAL	46.18 %w/v		Exact identifier — unii candidate 44 equally ranked IID candidates
MANNITOL	MANNITOL	3OWL53L36A	INJECTION, POWDER, FOR SUSPENSION / INTRAMUSCULAR		164 mg	Exact identifier — unii candidate 65 equally ranked IID candidates
MANNITOL	MANNITOL	3OWL53L36A	INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS	35 mg		Exact identifier — unii candidate 65 equally ranked IID candidates
SILICON DIOXIDE	SILICON DIOXIDE	ETJ7Z6XBU4	TABLET, EXTENDED RELEASE / ORAL		450 mg	Exact identifier — unii candidate 49 equally ranked IID candidates
SILICON DIOXIDE	SILICON DIOXIDE	ETJ7Z6XBU4	SOLUTION / ORAL		336 mg	Exact identifier — unii candidate 49 equally ranked IID candidates
SILICON DIOXIDE	SILICON DIOXIDE	ETJ7Z6XBU4	FILM, EXTENDED RELEASE / TRANSDERMAL	49 mg		Exact identifier — unii candidate 49 equally ranked IID candidates
MANNITOL	MANNITOL	3OWL53L36A	SUSPENSION/ DROPS / OPHTHALMIC	3.3 %w/v		Exact identifier — unii candidate 65 equally ranked IID candidates
MANNITOL	MANNITOL	3OWL53L36A	SOLUTION, CONCENTRATE / INTRAVENOUS		220 mg	Exact identifier — unii candidate 65 equally ranked IID candidates
MANNITOL	MANNITOL	3OWL53L36A	INJECTION, POWDER, FOR SOLUTION / PARENTERAL	200 mg		Exact identifier — unii candidate 65 equally ranked IID candidates
MAGNESIUM STEARATE	MAGNESIUM STEARATE	70097M6I30	CAPSULE, EXTENDED RELEASE / ORAL		117 mg	Exact identifier — unii candidate 39 equally ranked IID candidates
COPOVIDONE	COPOVIDONE K25-31	D9C330MD8B	TABLET, ORALLY DISINTEGRATING / ORAL		35 mg	Exact identifier — unii candidate 16 equally ranked IID candidates
MANNITOL	MANNITOL	3OWL53L36A	SOLUTION, GEL FORMING, EXTENDED RELEASE / OPHTHALMIC	4.35 %w/w		Exact identifier — unii candidate 65 equally ranked IID candidates
MANNITOL	MANNITOL	3OWL53L36A	SOLUTION / ORAL		869 mg	Exact identifier — unii candidate 65 equally ranked IID candidates
LACTOSE	LACTOSE	J2B2A4N98G	INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS	133 mg		Exact identifier — unii candidate 36 equally ranked IID candidates
LACTOSE	LACTOSE	J2B2A4N98G	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRACAVITARY	193.8 mg		Exact identifier — unii candidate 36 equally ranked IID candidates
MANNITOL	MANNITOL	3OWL53L36A	TABLET, FILM COATED / ORAL		2309 mg	Exact identifier — unii candidate 65 equally ranked IID candidates
MANNITOL	MANNITOL	3OWL53L36A	SOLUTION/ DROPS / OPHTHALMIC	4.6 %w/v		Exact identifier — unii candidate 65 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINE	MICROCRYSTALLINE CELLULOSE	OP1R32D61U	CAPSULE / ORAL		2169 mg	Exact identifier — unii candidate 28 equally ranked IID candidates
MAGNESIUM STEARATE	MAGNESIUM STEARATE	70097M6I30	TABLET, FILM COATED, EXTENDED RELEASE / ORAL		53 mg	Exact identifier — unii candidate 39 equally ranked IID candidates
LACTOSE	LACTOSE	J2B2A4N98G	TABLET, EXTENDED RELEASE / ORAL	400 mg		Exact identifier — unii candidate 36 equally ranked IID candidates
MAGNESIUM STEARATE	MAGNESIUM STEARATE	70097M6I30	CAPSULE, DELAYED RELEASE / ORAL		1060 mg	Exact identifier — unii candidate 39 equally ranked IID candidates
LACTOSE	LACTOSE	J2B2A4N98G	TABLET, EFFERVESCENT / ORAL	96.5 mg		Exact identifier — unii candidate 36 equally ranked IID candidates
SORBITOL	SORBITOL	506T60A25R	SUSPENSION / ORAL		45000 mg	Exact identifier — unii candidate 44 equally ranked IID candidates
MANNITOL	MANNITOL	3OWL53L36A	GRANULE, FOR SUSPENSION / ORAL		6000 mg	Exact identifier — unii candidate 65 equally ranked IID candidates
SORBITOL	SORBITOL	506T60A25R	LIQUID / TOPICAL	1 %w/w		Exact identifier — unii candidate 44 equally ranked IID candidates
MAGNESIUM STEARATE	MAGNESIUM STEARATE	70097M6I30	TABLET, EXTENDED RELEASE / ORAL		173 mg	Exact identifier — unii candidate 39 equally ranked IID candidates
MAGNESIUM STEARATE	MAGNESIUM STEARATE	70097M6I30	POWDER / TOPICAL		104 mg	Exact identifier — unii candidate 39 equally ranked IID candidates
SILICON DIOXIDE	SILICON DIOXIDE	ETJ7Z6XBU4	GRANULE, FOR SUSPENSION / ORAL		200 mg	Exact identifier — unii candidate 49 equally ranked IID candidates
SORBITOL	SORBITOL	506T60A25R	INJECTION / INTRA-ARTICULAR	45 %w/v		Exact identifier — unii candidate 44 equally ranked IID candidates
SILICON DIOXIDE	SILICON DIOXIDE	ETJ7Z6XBU4	PASTE / DENTAL	34 %w/w		Exact identifier — unii candidate 49 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINE	MICROCRYSTALLINE CELLULOSE	OP1R32D61U	CAPSULE, COATED PELLETS / ORAL		456 mg	Exact identifier — unii candidate 28 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINE	MICROCRYSTALLINE CELLULOSE	OP1R32D61U	SUSPENSION / ORAL		1600 mg	Exact identifier — unii candidate 28 equally ranked IID candidates
COPOVIDONE	COPOVIDONE K25-31	D9C330MD8B	TABLET, CHEWABLE / ORAL		5 mg	Exact identifier — unii candidate 16 equally ranked IID candidates
SILICON DIOXIDE	SILICON DIOXIDE	ETJ7Z6XBU4	CAPSULE, COATED / ORAL		3 mg	Exact identifier — unii candidate 49 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINE	MICROCRYSTALLINE CELLULOSE	OP1R32D61U	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL		1576 mg	Exact identifier — unii candidate 28 equally ranked IID candidates
SORBITOL	SORBITOL	506T60A25R	CREAM, AUGMENTED / TOPICAL	15 %w/w		Exact identifier — unii candidate 44 equally ranked IID candidates
SORBITOL	SORBITOL	506T60A25R	GUM, CHEWING / ORAL		6168 mg	Exact identifier — unii candidate 44 equally ranked IID candidates
SILICON DIOXIDE	SILICON DIOXIDE	ETJ7Z6XBU4	SUSPENSION, EXTENDED RELEASE / ORAL		70 mg	Exact identifier — unii candidate 49 equally ranked IID candidates
SORBITOL	SORBITOL	506T60A25R	INJECTION / INTRASYNOVIAL	45 %w/v		Exact identifier — unii candidate 44 equally ranked IID candidates

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
e17019f3-d2e9-4920-b6ca-985a89f5e6bf			1999abf5-0817-44cd-aceb-b20e910e3064	2012-10-30	Warnings	Exact identifier spl id: e17019f3-d2e9-4920-b6ca-985a89f5e6bf spl set id: 1999abf5-0817-44cd-aceb-b20e910e3064

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.